Adam R Coughlin1, Tyler J Willman1, Samuel P Gubbels2. 1. Division of Otolaryngology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 2. Department of Otolaryngology, University of Colorado School of Medicine, Aurora, Colorado.
Abstract
OBJECTIVE: To determine the long-term hearing preservation rate for spontaneous vestibular schwannoma treated by primary radiotherapy. DATA SOURCES: The MEDLINE/PubMed, Web of Science, Cochrane Reviews, and EMBASE databases were searched using a comprehensive Boolean keyword search developed in conjunction with a scientific librarian. English language papers published from 2000 to 2016 were evaluated. STUDY SELECTION: Inclusion criteria: full articles, pretreatment and posttreatment audiograms or audiogram based scoring system, vestibular schwannoma only tumor type, reported time to follow-up, published after 1999, use of either Gamma Knife or linear accelerator radiotherapy. EXCLUSION CRITERIA: case report or series with fewer than five cases, inadequate audiometric data, inadequate time to follow-up, neurofibromatosis type 2 exceeding 10% of study population, previous treatment exceeding 10% of study population, repeat datasets, use of proton beam therapy, and non-English language. DATA EXTRACTION: Two reviewers independently analyzed papers for inclusion. Class A/B, 1/2 hearing was defined as either pure tone average less than or equal to 50 db with speech discrimination score more than or equal to 50%, American Academy of Otolaryngology-Head & Neck Surgery (AAO-HNS) Hearing Class A or B, or Gardner-Robertson Grade I or II. Aggregate data were used when individual data were not specified. DATA SYNTHESIS: Means were compared with student t test. CONCLUSIONS: Forty seven articles containing a total of 2,195 patients with preserved Class A/B, 1/2 hearing were identified for analysis. The aggregate crude hearing preservation rate was 58% at an average reporting time of 46.6 months after radiotherapy treatment. Analysis of time-based reporting shows a clear trend of decreased hearing preservation extending to 10-year follow-up. This data encourages a future long-term controlled trial.
OBJECTIVE: To determine the long-term hearing preservation rate for spontaneous vestibular schwannoma treated by primary radiotherapy. DATA SOURCES: The MEDLINE/PubMed, Web of Science, Cochrane Reviews, and EMBASE databases were searched using a comprehensive Boolean keyword search developed in conjunction with a scientific librarian. English language papers published from 2000 to 2016 were evaluated. STUDY SELECTION: Inclusion criteria: full articles, pretreatment and posttreatment audiograms or audiogram based scoring system, vestibular schwannoma only tumor type, reported time to follow-up, published after 1999, use of either Gamma Knife or linear accelerator radiotherapy. EXCLUSION CRITERIA: case report or series with fewer than five cases, inadequate audiometric data, inadequate time to follow-up, neurofibromatosis type 2 exceeding 10% of study population, previous treatment exceeding 10% of study population, repeat datasets, use of proton beam therapy, and non-English language. DATA EXTRACTION: Two reviewers independently analyzed papers for inclusion. Class A/B, 1/2 hearing was defined as either pure tone average less than or equal to 50 db with speech discrimination score more than or equal to 50%, American Academy of Otolaryngology-Head & Neck Surgery (AAO-HNS) Hearing Class A or B, or Gardner-Robertson Grade I or II. Aggregate data were used when individual data were not specified. DATA SYNTHESIS: Means were compared with student t test. CONCLUSIONS: Forty seven articles containing a total of 2,195 patients with preserved Class A/B, 1/2 hearing were identified for analysis. The aggregate crude hearing preservation rate was 58% at an average reporting time of 46.6 months after radiotherapy treatment. Analysis of time-based reporting shows a clear trend of decreased hearing preservation extending to 10-year follow-up. This data encourages a future long-term controlled trial.
Authors: Melandee Brown; Michael Ruckenstein; Douglas Bigelow; Kevin Judy; Vasthi Wilson; Michelle Alonso-Basanta; John Y K Lee Journal: Neurosurgery Date: 2011-09 Impact factor: 4.654
Authors: H M Kooy; S F Dunbar; N J Tarbell; E Mannarino; N Ferarro; S Shusterman; M Bellerive; L Finn; C V McDonough; J S Loeffler Journal: Int J Radiat Oncol Biol Phys Date: 1994-10-15 Impact factor: 7.038
Authors: Sana D Karam; Alexander Tai; Alexis Strohl; Matthew K Steehler; Abdul Rashid; Gregory Gagnon; K William Harter; Ann K Jay; Sean P Collins; Jeffrey H Kim; Walter Jean Journal: Front Oncol Date: 2013-05-17 Impact factor: 6.244
Authors: Anurag Saraf; Luke R G Pike; Kevin H Franck; Nora K Horick; Beow Y Yeap; Barbara C Fullerton; Irene S Wang; Mohamed E Abazeed; Michael J McKenna; William A Mehan; Scott R Plotkin; Jay S Loeffler; Helen A Shih Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315
Authors: Dominique Valérie Clarence de Jel; Ernst J Smid; Tristan P C van Doormaal; Hans G X M Thomeer Journal: J Int Adv Otol Date: 2021-09 Impact factor: 1.017
Authors: Maike Küchler; Rami A El Shafie; Sebastian Adeberg; Klaus Herfarth; Laila König; Kristin Lang; Juliane Hörner-Rieber; Peter Karl Plinkert; Wolfgang Wick; Felix Sahm; Simon David Sprengel; Jürgen Debus; Denise Bernhardt Journal: Cancers (Basel) Date: 2022-04-10 Impact factor: 6.575
Authors: Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-01